Cargando…
Targeted therapies in cancer /
Since the year 2000, exciting developments in cancer therapy have occurred. For decades in the 20th century, the hallmark of medical treatment for cancer had been cytotoxic chemotherapy, with drugs targeting rapidly dividing cells, including cancer cells but also certain normal tissues. As a result,...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
New York :
Nova Biomedical,
[2014]
|
| Colección: | Cancer etiology, diagnosis, and treatments.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | EBSCO_ocn891076489 | ||
| 003 | OCoLC | ||
| 005 | 20231017213018.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 140922s2014 nyu ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d OCLCF |d E7B |d YDXCP |d OCLCQ |d EBLCP |d OCLCQ |d DEBSZ |d OCLCQ |d AGLDB |d OCLCQ |d VTS |d STF |d AU@ |d OCLCQ |d K6U |d OCLCO |d LUU |d OCLCQ |d OCLCO | ||
| 019 | |a 891398303 |a 899992256 |a 916949676 |a 923676471 |a 928196027 |a 963743454 |a 967761966 | ||
| 020 | |a 9781633216877 |q (electronic bk.) | ||
| 020 | |a 163321687X |q (electronic bk.) | ||
| 020 | |z 1633216764 | ||
| 020 | |z 9781633216761 | ||
| 029 | 1 | |a DEBBG |b BV042796051 | |
| 029 | 1 | |a DEBSZ |b 472845705 | |
| 035 | |a (OCoLC)891076489 |z (OCoLC)891398303 |z (OCoLC)899992256 |z (OCoLC)916949676 |z (OCoLC)923676471 |z (OCoLC)928196027 |z (OCoLC)963743454 |z (OCoLC)967761966 | ||
| 050 | 4 | |a RC270.8 |b .L33 2014eb | |
| 060 | 4 | |a QZ 267 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.99/406 |2 23 |
| 049 | |a UAMI | ||
| 100 | 1 | |a Lacroix, Marc, |d 1963- |e author. | |
| 245 | 1 | 0 | |a Targeted therapies in cancer / |c Marc Lacroix, Ph. D. |
| 264 | 1 | |a New York : |b Nova Biomedical, |c [2014] | |
| 264 | 4 | |c ©2014 | |
| 300 | |a 1 online resource (xi, 233 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Cancer etiology, diagnosis, and treatments | |
| 504 | |a Includes bibliographical references and index. | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a TARGETED THERAPIES IN CANCER; TARGETED THERAPIES IN CANCER; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Chapter 1: Innovation in the Biopharmaceutical Pipeline; Abstract; Introduction; Drug Discovery and Development Process; Discovery and Preclinical Testing; Clinical Testing in Human Subjects; Regulatory Review and Approval; Post-Approval Research and Monitoring; References; Chapter 2: The Diversity of Targeted Cancer Drugs Recently Approved by the FDA; Abstract; Introduction; 1) Tyrosine Kinase (TK) Inhibitors (TKIs). | |
| 505 | 8 | |a 2) Serine/Threonine Kinase Inhibitors (STKIs)3) Monoclonal Antibodies (MAbs); 4) Decoy Vascular Endothelial Growth Factor Receptor; 5) Immunomodulatory Agents; 7) Antimetabolites; 8) Enzymes; 9) Histone Deacetylase (HDAC) Inhibitors; 10) Proteasome Inhibitors; 11) Hedgehog Pathway Inhibitor; 12) Protein Translation Inhibitor; 13) Hormone (Androgen Deprivation) Therapy; 14) Microtubule Targeting Agents; 15) Autologous Cellular Immunotherapy; 16) Radiopharmaceutical Compound; References; Chapter 3: Chronological List of Targeted Cancer Drugs Approved by the FDA; Abstract; Introduction. | |
| 505 | 8 | |a ReferenceChaper 4: Targeted Therapies: Detailed Description; Abstract; Introduction; Rituximab; Trastuzumab; Imatinib; Alemtuzumab; Ibritumomab; Gefitinib; Tositumomab; Azacitidine; Pemetrexed; Cetuximab; Bevacizumab; Erlotinib; Nelarabine; Sorafenib; Pegaspargase; Lenalidomide; Sunitinib; Dasatinib; Panitumumab; Vorinostat; Bortezomib; Decitabine; Lapatinib; Temsirolimus; Ixabepilone; Nilotinib; Degarelix; Everolimus; Pralatrexate; Pazopanib; Ofatumumab; Romidepsin; Cabazitaxel; Sipuleucel-T; Eribulin; Denosumab; Ipilimumab; Vandetanib; Abiraterone; Vemurafenib; Brentuximab; Crizotinib. | |
| 505 | 8 | |a Asparaginase Erwinia chrysanthemiAxitinib; Vismodegib; Pertuzumab; Carfilzomib; Ziv-aflibercept; Enzalutamide; Bosutinib; Regorafenib; Omacetaxine; Cabozantinib; Ponatinib; Pomalidomide; Ado-trastuzumab Emtansine; Radium Ra223; Trametinib; Dabrafenib; Afatinib; Obinutuzumab; Ibrutinib; Ramucirumab; Ceritinib; Chapter 5: Targeted Therapy for Chronic Lymphocytic Leukemia (CLL); Abstract; Introduction; Rituximab; Rituximab As a Single Agent; Chemoimmunotherapy with Rituximab; Alemtuzumab; Ofatumumab; Ofatumumab and Chlorambucil; Obinutuzumab; Ibrutinib; Conclusion; References. | |
| 505 | 8 | |a Chapter 6: Targeted Therapy for HER-2-Positive Breast CancerAbstract; Introduction; Trastuzumab; Lapatinib; Approved for HER-2-Overexpressing Breast Cancer; Approved for Hormone-Positive and HER-2-Positive Advanced Breast Cancer; Pertuzumab; Ado-Trastuzumab Emtansine; Conclusion; References; Chapter 7: Targeted Therapy for Metastatic Breast Cancer: Varia; Abstract; Introduction; Ixabepilone; Eribulin; Everolimus; Conclusion; References; Chapter 8: Targeted Therapy for Chronic Myelogenous Leukemia (CML); Abstract; Introduction; Imatinib; Imatinib and Resistance; Nilotinib; Dasatinib; Bosutinib. | |
| 520 | |a Since the year 2000, exciting developments in cancer therapy have occurred. For decades in the 20th century, the hallmark of medical treatment for cancer had been cytotoxic chemotherapy, with drugs targeting rapidly dividing cells, including cancer cells but also certain normal tissues. As a result, many patients experienced the ""classic"" toxicities of alopecia, gastrointestinal symptoms and/or myelosuppression. In the last years, however, clinical research has been strongly occupied with the identification of mutations and aberrations concerning molecular pathways in cancer and their altera. | ||
| 590 | |a eBooks on EBSCOhost |b EBSCO eBook Subscription Academic Collection - Worldwide | ||
| 650 | 0 | |a Cancer |x Treatment. | |
| 650 | 0 | |a Drug targeting. | |
| 650 | 2 | |a Drug Delivery Systems | |
| 650 | 6 | |a Cancer |x Traitement. | |
| 650 | 6 | |a Médicaments |x Ciblage. | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Cancer |x Treatment |2 fast | |
| 650 | 7 | |a Drug targeting |2 fast | |
| 776 | 0 | 8 | |i Print version: |t Targeted therapies in cancer |z 1633216764 |w (OCoLC)883649715 |
| 830 | 0 | |a Cancer etiology, diagnosis, and treatments. | |
| 856 | 4 | 0 | |u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=836658 |z Texto completo |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL2119861 | ||
| 938 | |a ebrary |b EBRY |n ebr10919002 | ||
| 938 | |a EBSCOhost |b EBSC |n 836658 | ||
| 938 | |a YBP Library Services |b YANK |n 11975975 | ||
| 994 | |a 92 |b IZTAP | ||